TITLE:
Cost-Utility Analysis of Liraglutide in Type 2 Diabetes Patients in China after Chinese Reformation of Medical Care System
AUTHORS:
Gaoyu Xie, Suning Zhao
KEYWORDS:
Liraglutide, Type 2 Diabetes Mellitus, Markov Model, Cost-Effectiveness Analysis, Chinese Reformation on Medical Insurance
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.6 No.12,
December
5,
2018
ABSTRACT: Objectives: The
cost-utility analysis of Liraglutide is aimed at evaluating whether Liraglutide
is cost-effective or not after Chinese reformation on medical insurance. The
analysis is based on the results of clinical trial conducted in Asia. Methods:
We applied a Markov model to estimate the quality-adjusted life years, medical
cost and incidence of diabetes-related complications for patients receiving the
Liraglutide as an add-on to the metformin treatment. Baseline characteristics
were taken
from a China’s study while the treatment effect is from an Asian study. The
related medical cost and utility score were obtained from a local study in
China. Having set 30 years’ simulations, the incremental cost-effectiveness
ratio was calculated comparing with glimepiride treatment. The ratio would be
compared with the willingness to pay for a quality-adjusted-life-year (QALY)
which is three times of the GDP per capita in Beijing. Sensitivity analysis was
also performed. Result: During a period of 30 years, the base-case
analysis which takes discount rate at 3% shows that Liraglutide 1.8 mg results in an average
incremental cost of CNY 82,671.49, an improvement in 0.12 QALYs and a reduction
of incidence of diabetes-related complications comparing to glimepiride. The
associated incremental cost-effectiveness ratio is CNY 688,929.08. Conclusion:
Long-term project shows that taking Liraglutide as an add-on to the metformin
treatment will lead to increasing quality-adjusted life years and reduction of incidence of diabetes-related
complications. When the price of Liraglutide is reduced by 43 percent in
China’s yuan, Liraglutide will be cost-effective in China from the healthcare
system perspective taking three times of GDP per capita as our WTP threshold.